Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Artificial intelligence and big data for precision regenerative medicine in knee osteoarthritis: endotyping, responder prediction, and clinical translation.

Zheng L., Li J., Wang H., Zhou J., Zhao P., Li Q.

Narrative Review on Knee Osteoarthritis, Osteoarthritis, Scar, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Bioeng Biotechnol (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42529139
DOI
10.3389/fbioe.2026.1899487

Abstract (original English)

Knee osteoarthritis (KOA) is a heterogeneous whole-joint disease, and regenerative and orthobiologic therapies such as platelet-rich plasma (PRP), mesenchymal stem cells (MSCs), bone marrow aspirate concentrate (BMAC), microfragmented adipose tissue (MFAT), and extracellular vesicles (EVs) show variable clinical effects. This variability reflects a dual heterogeneity: patients differ in structural damage, inflammation, metabolism, biomechanics, pain mechanisms, and molecular endotypes, while therapeutic products differ in composition, dose, viability, secretome, and manufacturing protocols. This Mini Review discusses how multimodal characterization of both patients and products may provide the data foundation for precision regenerative medicine in KOA. Imaging, radiomics, biomechanics, multi-omics, and product-quality attributes can be integrated to define meaningful endotypes and support responder prediction. We critically evaluate current artificial intelligence (AI) applications and demonstrate that, although AI has advanced automated imaging assessment and KOA progression prediction, direct evidence for regenerative treatment-response prediction remains scarce. Existing models are largely limited to PRP, whereas validated AI models for MSC-, BMAC-, MFAT-, and EV-based therapies are lacking. Clinical translation will require more than high discrimination metrics. Explainable

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research